These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 27783139

  • 1. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
    Garrett M, Taylor T, Mould DR, Amantea MA, Chen Y, Ingrosso A, Pithavala YK.
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1131-1141. PubMed ID: 27783139
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
    Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ.
    J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
    [Abstract] [Full Text] [Related]

  • 6. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso, Guidi M, Khoudour N, Pascaline Boudou-Rouquette, Fabre E, Tlemsani C, Arrondeau J, François Goldwasser, Vidal M, Schneider MP, Wagner AD, Widmer N, Blanchet B, Csajka C.
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of axitinib on the QT interval in healthy volunteers.
    Ruiz-Garcia A, Houk BE, Pithavala YK, Toh M, Sarapa N, Tortorici MA.
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):619-28. PubMed ID: 25589220
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.
    Chen Y, Rini BI, Bair AH, Mugundu GM, Pithavala YK.
    Clin Pharmacokinet; 2015 Apr; 54(4):397-407. PubMed ID: 25343945
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic evaluation of axitinib.
    Patson B, B Cohen R, Olszanski AJ.
    Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):259-70. PubMed ID: 22248343
    [Abstract] [Full Text] [Related]

  • 14. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
    Chen R, Li J, Hu WW, Wang ML, Zou SL, Miao LY.
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
    [Abstract] [Full Text] [Related]

  • 15. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
    Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Grünwald V.
    Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
    [Abstract] [Full Text] [Related]

  • 16. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.
    Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ.
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):563-70. PubMed ID: 19603168
    [Abstract] [Full Text] [Related]

  • 17. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
    Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T.
    Med Oncol; 2018 Mar 09; 35(4):51. PubMed ID: 29524031
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ, Pithavala Y, Bu HZ, Kang P, Hee B, Deese AJ, Pool WF, Klamerus KJ, Wu EY, Dalvie DK.
    Drug Metab Dispos; 2014 May 09; 42(5):918-31. PubMed ID: 24608633
    [Abstract] [Full Text] [Related]

  • 19. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A, Orillard E, Mouillet G, Calcagno F, Devillard N, Bouchet S, Royer B.
    Cancer Chemother Pharmacol; 2017 Jun 09; 79(6):1273-1276. PubMed ID: 28451830
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Emoto-Yamamoto Y, Iida S, Kawanishi T, Fukuoka M.
    J Clin Pharm Ther; 2015 Apr 09; 40(2):232-9. PubMed ID: 25402940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.